Professor of Medicinal Chemistry
- Bernard Taylor Fellow and Tutor in Organic Chemistry
My work focuses on the discovery of new drug targets and mechanisms, and the translation of these findings into new clinical candidates.
Through several successful multidisciplinary research collaborations, my team works in a range of therapeutic areas including identifying small molecules to upregulate utrophin for the treatment of Duchenne Muscular Dystrophy (DMD), new anti-cancer agents and agents to stimulate endogenous cell populations for regenerative medicine.
I have co-founded two spin-out companies to date, MuOx Ltd (acquired by Summit plc in November 2013), for the development of new small molecule utrophin modulators for DMD therapy, and OxStem Ltd, a company to translate our research findings in small molecule manipulation of stem cells for regenerative medicine. Most recently, OxStem Ltd raised a record £16.9M to identify new classes of drugs that can re-programme or stimulate existing endogenous cells to repair tissues in age-related conditions including cancer, neurodegenerative diseases and heart failure.
As well as my active teaching commitments within the Departments of Pharmacology and Chemistry and at St John’s College, I am a member of, and contribute to, the Oxford Stem Cell Institute (OSCI), the British Heart Foundation Centre of Research Excellence (BHF CRE), and the Cancer Research UK Oxford Centre – supporting at all levels including research and training.
Biased agonists of GPR84 and insights into biological control.
Luscombe VB. et al, (2023), Br J Pharmacol
Development of Highly Potent, G-Protein Pathway Biased, Selective, and Orally Bioavailable GPR84 Agonists.
Wang P. et al, (2023), J Med Chem
Modified minimal-size fragments of heparan sulfate as inhibitors of endosulfatase-2 (Sulf-2).
Kennett A. et al, (2023), Chem Commun (Camb)
Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's.
Brimblecombe KR. et al, (2023), Eur J Neurosci
Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines.
Josa-Culleré L. et al, (2023), Eur J Med Chem, 258